TY - JOUR A1 - Engel, Katharina A1 - Rudelius, Martina A1 - Slawska, Jolanta A1 - Jacobs, Laura A1 - Abhari, Behnaz Ahangarian A1 - Altmann, Bettina A1 - Kurutz, Julia A1 - Rathakrishnan, Abirami A1 - Fernández-Sáiz, Vanesa A1 - Brunner, Andrä A1 - Targosz, Bianca-Sabrina A1 - Loewecke, Felicia A1 - Gloeckner, Christian Johannes A1 - Ueffing, Marius A1 - Fulda, Simone A1 - Pfreundschuh, Michael A1 - Trümper, Lorenz A1 - Klapper, Wolfram A1 - Keller, Ulrich A1 - Jost, Philipp J. A1 - Rosenwald, Andreas A1 - Peschel, Christian A1 - Bassermann, Florian T1 - USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma JF - EMBO Molecular Medicine N2 - The mitotic spindle assembly checkpoint (SAC) maintains genome stability and marks an important target for antineoplastic therapies. However, it has remained unclear how cells execute cell fate decisions under conditions of SAC‐induced mitotic arrest. Here, we identify USP9X as the mitotic deubiquitinase of the X‐linked inhibitor of apoptosis protein (XIAP) and demonstrate that deubiquitylation and stabilization of XIAP by USP9X lead to increased resistance toward mitotic spindle poisons. We find that primary human aggressive B‐cell lymphoma samples exhibit high USP9X expression that correlate with XIAP overexpression. We show that high USP9X/XIAP expression is associated with shorter event‐free survival in patients treated with spindle poison‐containing chemotherapy. Accordingly, aggressive B‐cell lymphoma lines with USP9X and associated XIAP overexpression exhibit increased chemoresistance, reversed by specific inhibition of either USP9X or XIAP. Moreover, knockdown of USP9X or XIAP significantly delays lymphoma development and increases sensitivity to spindle poisons in a murine Eμ‐Myc lymphoma model. Together, we specify the USP9X–XIAP axis as a regulator of the mitotic cell fate decision and propose that USP9X and XIAP are potential prognostic biomarkers and therapeutic targets in aggressive B‐cell lymphoma. KW - B‐cell lymphoma KW - mitosis KW - ubiquitin KW - USP9X KW - XIAP Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-165016 VL - 8 ER - TY - JOUR A1 - Buchheim, Mark A. A1 - Keller, Alexander A1 - Koetschan, Christian A1 - Förster, Frank A1 - Merget, Benjamin A1 - Wolf, Matthias T1 - Internal Transcribed Spacer 2 (nu ITS2 rRNA) Sequence-Structure Phylogenetics: Towards an Automated Reconstruction of the Green Algal Tree of Life JF - PLoS ONE N2 - Background: Chloroplast-encoded genes (matK and rbcL) have been formally proposed for use in DNA barcoding efforts targeting embryophytes. Extending such a protocol to chlorophytan green algae, though, is fraught with problems including non homology (matK) and heterogeneity that prevents the creation of a universal PCR toolkit (rbcL). Some have advocated the use of the nuclear-encoded, internal transcribed spacer two (ITS2) as an alternative to the traditional chloroplast markers. However, the ITS2 is broadly perceived to be insufficiently conserved or to be confounded by introgression or biparental inheritance patterns, precluding its broad use in phylogenetic reconstruction or as a DNA barcode. A growing body of evidence has shown that simultaneous analysis of nucleotide data with secondary structure information can overcome at least some of the limitations of ITS2. The goal of this investigation was to assess the feasibility of an automated, sequence-structure approach for analysis of IT2 data from a large sampling of phylum Chlorophyta. Methodology/Principal Findings: Sequences and secondary structures from 591 chlorophycean, 741 trebouxiophycean and 938 ulvophycean algae, all obtained from the ITS2 Database, were aligned using a sequence structure-specific scoring matrix. Phylogenetic relationships were reconstructed by Profile Neighbor-Joining coupled with a sequence structure-specific, general time reversible substitution model. Results from analyses of the ITS2 data were robust at multiple nodes and showed considerable congruence with results from published phylogenetic analyses. Conclusions/Significance: Our observations on the power of automated, sequence-structure analyses of ITS2 to reconstruct phylum-level phylogenies of the green algae validate this approach to assessing diversity for large sets of chlorophytan taxa. Moreover, our results indicate that objections to the use of ITS2 for DNA barcoding should be weighed against the utility of an automated, data analysis approach with demonstrated power to reconstruct evolutionary patterns for highly divergent lineages. KW - RBCL Gene-sequences KW - Colonial volvocales chlorophyta KW - 26S RDNA Data KW - Land plants KW - Molecular systematics KW - Secondary structure KW - Nuclear RDNA KW - DNA KW - Barcodes KW - Dasycladales chlorophyta KW - Profile distances Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-140866 VL - 6 IS - 2 ER - TY - JOUR A1 - Franke, Katharina A1 - Vilne, Baiba A1 - da Costa, Olivia Prazeres A1 - Rudelius, Martina A1 - Peschel, Christian A1 - Oostendorp, Robert A. J. A1 - Keller, Ulrich T1 - In vivo hematopoietic Myc activation directs a transcriptional signature in endothelial cells within the bone marrow microenvironment JF - Oncotarget N2 - Cancer pathogenesis involves tumor-intrinsic genomic aberrations and tumor-cell extrinsic mechanisms such as failure of immunosurveillance and structural and functional changes in the microenvironment. Using Myc as a model oncogene we established a conditional mouse bone marrow transduction/transplantation model where the conditional activation of the oncoprotein Myc expressed in the hematopoietic system could be assessed for influencing the host microenvironment. Constitutive ectopic expression of Myc resulted in rapid onset of a lethal myeloproliferative disorder with a median survival of 21 days. In contrast, brief 4-day Myc activation by means of the estrogen receptor (ER) agonist tamoxifen did not result in gross changes in the percentage/frequency of hematopoietic lineages or hematopoietic stem/progenitor cell (HSPC) subsets, nor did Myc activation significantly change the composition of the non-hematopoietic microenvironment defined by phenotyping for CD31, ALCAM, and Sca-1 expression. Transcriptome analysis of endothelial CD45-Ter119-cells from tamoxifen-treated MycER bone marrow graft recipients revealed a gene expression signature characterized by specific changes in the Rho subfamily pathway members, in the transcription-translation-machinery and in angiogenesis. In conclusion, intra-hematopoietic Myc activation results in significant transcriptome alterations that can be attributed to oncogene-induced signals from hematopoietic cells towards the microenvironment, e. g. endothelial cells, supporting the idea that even pre-leukemic HSPC highjack components of the niche which then could protect and support the cancer-initiating population. KW - stem-cells KW - mutations KW - C-Myc KW - Rho-GTPases KW - niche KW - leukemia KW - target KW - growth KW - cycle KW - apoptosis, Myc KW - microenvironment KW - endothelial cells Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-145844 VL - 6 IS - 26 SP - 21827 EP - 21839 ER - TY - JOUR A1 - Koetschan, Christian A1 - Foerster, Frank A1 - Keller, Alexander A1 - Schleicher, Tina A1 - Ruderisch, Benjamin A1 - Schwarz, Roland A1 - Mueller, Tobias A1 - Wolf, Matthias A1 - Schultz, Joerg T1 - The ITS2 Database III-sequences and structures for phylogeny N2 - The internal transcribed spacer 2 (ITS2) is a widely used phylogenetic marker. In the past, it has mainly been used for species level classifications. Nowadays, a wider applicability becomes apparent. Here, the conserved structure of the RNA molecule plays a vital role. We have developed the ITS2 Database (http://its2.bioapps .biozentrum.uni-wuerzburg.de) which holds information about sequence, structure and taxonomic classification of all ITS2 in GenBank. In the new version, we use Hidden Markov models (HMMs) for the identification and delineation of the ITS2 resulting in a major redesign of the annotation pipeline. This allowed the identification of more than 160 000 correct full ength and more than 50 000 partial structures. In the web interface, these can now be searched with a modified BLAST considering both sequence and structure, enabling rapid taxon sampling. Novel sequences can be annotated using the HMM based approach and modelled according to multiple template structures. Sequences can be searched for known and newly identified motifs. Together, the database and the web server build an exhaustive resource for ITS2 based phylogenetic analyses. KW - Biologie Y1 - 2010 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-68390 ER - TY - JOUR A1 - Herrmann, Ken A1 - Buck, Andreas K. A1 - Schuster, Tibor A1 - Abbrederis, Kathrin A1 - Blümel, Christina A1 - Santi, Ivan A1 - Rudelius, Martina A1 - Wester, Hans-Jürgen A1 - Peschel, Christian A1 - Schwaiger, Markus A1 - Dechow, Tobias A1 - Keller, Ulrich T1 - Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL JF - Oncotarget N2 - Despite improved survival in the Rituximab (R) era, a considerable number of patients with diffuse large B-cell lymphoma (DLBCL) ultimately die from the disease. Functional imaging using [18F]fluorodeoxyglucose-PET is suggested for assessment of residual viable tumor very early during treatment but is compromised by non-specific tracer retention in inflammatory lesions. The PET tracer [18F]fluorodeoxythymidine (FLT) as surrogate marker of tumor proliferation may overcome this limitation. We present results of a prospective clinical study testing FLT-PET as superior and early predictor of response to chemotherapy and outcome in DLBCL. 54 patients underwent FLT-PET prior to and one week after the start of R-CHOP chemotherapy. Repetitive FLT-PET imaging was readily implemented into the diagnostic work-up. Our data demonstrate that the reduction of FLT standard uptake valuemean (SUVmean) and SUVmax one week after chemotherapy was significantly higher in patients achieving complete response (CR, n=48; non-CR, n=6; p<0.006). Martingale-residual and Cox proportional hazard analyses showed a significant monotonous decrease of mortality risk with increasing change in SUV. Consistent with these results, early FLT-PET response showed relevant discriminative ability in predicting CR. In conclusion, very early FLT-PET in the course of R-CHOP chemotherapy is feasible and enables identification of patients at risk for treatment failure. KW - [18F]Fluorodeoxythymidine KW - FLT-PET KW - positron emission tomography KW - DLBCL KW - lymphoma Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-120659 SN - 1949-2553 VL - 5 IS - 12 ER - TY - THES A1 - Keller, Christian T1 - The role of dendritic cells in the immunoregulation of leishmaniasis - transfection of dendritic cells with mRNA encoding a molecularly defined parasitic antigen T1 - Die Rolle dendritischer Zellen in der Immunregulation der Leishmaniose - Transfektion dendritischer Zellen mit mRNA eines molekular definierten Parasitenantigens N2 - Die kutane Leishmaniose ist eine Infektionskrankheit, die besonders in tropischen und Wüstenregionen endemisch ist, mit einer Inzidenz von 1,5 Millionen Fällen im Jahr und einer Prävalenz von 12 Millionen Infizierten weltweit. Die Infektion kann durch den intrazellulären Parasiten Leishmania major hervorgerufen werden. Am Mausmodell ist die Krankheit ausführlich untersucht. Wie dabei deutlich wurde, ist für die Immunität gegen den Erreger die Induktion einer Klasse von Interferon (IFN)--produzierenden CD4+ T-Helfer-Zellen (TH1-Zellen) entscheidend, welche Makrophagen dazu aktivieren, die von ihnen beherbergten Parasiten abzutöten. Die Umlenkung der Immunantwort in Richtung einer schützenden TH1-Antwort wird auch der Schlüssel zu einem effektiven Impfstoff sein. Ex vivo mit Leishmanienantigenen beladene dendritische Zellen sind vor einiger Zeit als Vakzine gegen L. major-Infektionen beschrieben worden. Ein einzelnes rekombinantes Antigen, LeIF (Leishmania homologue of eukaryotic ribosomal initiation factor 4a), ein parasitäres Protein, das die IL-12-Produktion durch dendritische Zellen stimuliert und das als mikrobiell konserviertes Strukturmolekül (pattern-associated molecular pattern; PAMP) diskutiert wird, vermittelte dabei, zum Pulsen von dendritischen Zellen verwendet, einen schützenden TH1-abhängigen Effekt. Der Einsatz rekombinanter Proteine ist jedoch mit etlichen Nachteilen verbunden, weshalb andere Methoden zur Verabreichung von Antigenen entwickelt wurden. Aus der Tumorforschung ist unlängst die RNA-Elektroporation dendritischer Zellen als eine sichere und vielseitige Methode hervorgegangen, bei der eine große Anzahl von RNA-Molekülen, die für ein bestimmtes Antigen kodieren, durch einen elektrischen Impuls in das Cytosol dendritischer Zellen gelangt. Die vorliegende Arbeit beschreibt zum ersten Mal die Transfektion dendritischer Zellen mit RNA eines molekular definierten Parasitenantigens. Zunächst erfolgte die Etablierung eines standardisierten Protokolls für die RNA-Transfektion mit dem enhanced green fluorescent protein (EGFP) als Reporterantigen. EGFP-RNA war gut translatierbar in einem In-vitro-Translationssystem, und es konnten sowohl eine Zellinie (fetal skin-derived dendritic cells; FSDC) als auch primäre, aus Knochenmarkkulturen der Maus gewonnene dendritische Zellen (bone marrow-derived dendritic cells; BMDC) mit einem Anteil von bis zu 90% bzw. 75% effizient EGFP-transfiziert werden. In beiden Zelltypen wurde die maximale Transfektionseffizienz mit 20 µg RNA erreicht, die mit größeren Mengen an RNA nicht weiter zu steigern war. Die Höhe der Antigenexpression, gemessen als mittlere Fluoreszenzintensität (MFI) in der Durchflußzytometrie, war direkt proportional zur verwendeten RNA-Menge. In FSDC waren die Transfektionseffizienz und die MFI generell höher als in BMDC bei gleicher RNA-Menge. Zudem konnte gezeigt werden, daß eine Behandlung mit LPS die Kinetik beeinflußt: Die maximale Expression war höher und wurde auch eher erreicht, worauf zudem ein schnellerer Abfall folgte. In den Transfektionsexperimenten mit LeIF wurden zwei Varianten von LeIF-RNA verwendet: eine für die gesamte LeIF-Sequenz kodierende LeIF(fl)-RNA, und eine nur für die aminoterminale Hälfte der LeIF-Sequenz (226 Aminosäuren), dem immunogenen Teil des LeIF-Moleküls, kodierende LeIF(226)-RNA. Im Western Blot von Ganzzellysaten dendritischer Zellen war nur LeIF(fl) nach Transfektion nachzuweisen, wohingegen LeIF(226) in LeIF(226)-transfizierten BMDC nie nachzuweisen war. Da beide Konstrukte aber gut im zellfreien System translatierbar waren, stellte der fehlgeschlagene Nachweis von LeIF(226) kein Fehlschlagen der RNA-Translation, sondern vielmehr einen raschen Antigenabbau dar. Es bestand daher die Erwartung, daß LeIF(226)-transfizierte BMDC trotzdem in der Lage sein müßten, von LeIF(226) abgeleitete antigene Peptide an T-Zellen von mit rekombinantem LeIF (rLeIF) immunisierten BALB/c-Mäusen zu präsentieren. Diese Vermutung wurde durch Messung von IFN- in Stimulationsversuchen mit BMDC und T-Zellen bestätigt, die zeigten, daß am Tag 7 der Kultur mit rLeIF gepulste, LeIF(226)- und LeIF(fl)-transfizierte BMDC in der Tat antigenspezifisch T-Zellen aus LeIF-immunisierten Mäusen aktivierten. IL-4 hingegen wurde nicht produziert, was mit der Tatsache vereinbar ist, daß in Lymphknoten LeIF-vakzinierter Mäusen hauptsächlich T-Zellen vom TH1-Typ zu finden sind. In den Überständen LeIF-transfizierter BMDC-Kulturen, im Gegensatz zu rLeIF-gepulsten BMDC, waren die proinflammatorischen Zytokine IL-1β, IL-6, IL-10 und IL-12 nicht nachzuweisen. Dieser Effekt lag nicht am Elektroporationsvorgang, da die Zytokinproduktion von mit rekombinantem LeIF elektroporierten BMDC nur teilweise beeinträchtigt war. Die Expression von CD86 war nach LeIF-Transfektion zudem geringer als nach Pulsen mit rLeIF. LeIF-Transfektion führte mithin nicht zur Reifung dendritischer Zellen. LeIF-transfizierte BMDC könnten im Ergebnis als antigenspezifische Toleranzinduktoren fungiert haben, mit regulatorischen T-Zellen als Respondern. Der Effekt der Transfektion mit LeIF-RNA auf die immunstimulatorische Wirkung von BMDC war nicht signifikant erhöht, wenn BMDC am Tag 8 oder 9 der Kultur verwendet wurden. BMDC, die am Tag 8, und mehr noch am Tag 9 mit rLeIF gepulst wurden, induzierten hingegen eine energische T-Zell-Antwort. BMDC vom Tag 9 waren sogar in der Lage, naive T-Zellen zu aktivieren. Bevor eine starke, gegen LeIF gerichtete T-Zell-Antwort eingeleitet werden kann, müssen dendritische Zellen also letztlich – neben Präsentation des Antigens und Expression kostimulatorischer Moleküle – eine gewisse „Empfindlichkeit“ gegenüber dem Strukturmolekül LeIF besitzen, die mit ihrem Reifungsalter in Zusammenhang steht. Dieses dritte Signal wird nicht durch intrazelluläres LeIF nach Transfektion mit LeIF-RNA übermittelt, oder es wird unterdrückt. Darüber hinaus war nach Elektroporation von rLeIF die IL-12-Produktion von BMDC gänzlich aufgehoben, die Produktion von IL-1 bei höheren Antigendosen reduziert und die Produktion von IL-10 teilweise erhöht. Die Produktion von IL-6 war unbeeinflußt. Dieses veränderte Zytokinprofil legt eine Doppelnatur von LeIF als PAMP nahe: Neben der bei extrazellulärem Vorliegen von LeIF erwiesenen Eigenschaft, die Produktion von IL-12 zu stimulieren, welches die Resistenz des Wirtes gegen L. major steigert, könnte LeIF bei intrazellulärem Vorliegen auch zu Evasionsmechanismen des Parasiten vor dem Immunsystem des Wirtes beitragen, möglicherweise durch Wechselwirkung mit MAP (mitogen-activated protein)-Kinase-Signalwegen. Die Eigenschaften von LeIF als Adjuvans hängen also sowohl von der Verabreichungsmethode (Transfektion mit RNA bzw. Pulsen mit dem rekombinanten Protein) als auch vom Zielkompartiment (extra- bzw. intrazellulär) ab. Zusammenfassend konnte also in dieser Arbeit gezeigt werden, daß BMDC mit einem Parasitenantigen transfizierbar sind. Das Antigen wird dabei prozessiert und präsentiert, aber von dendritischen Zellen nicht als PAMP erkannt. Durch Transfektion mit antigenkodierender mRNA alleine werden mithin nicht alle notwendigen Signale für die Induktion einer potenten Immunantwort übermittelt. N2 - Cutaneous leishmaniasis is an infectious disease that is endemic especially in tropical and desert regions with an incidence of 1.5 million cases per year and a prevalence of 12 million people infected worldwide. The infection can be caused by the intracellular parasite Leishmania major. The disease has been studied extensively in the murine model. It has become apparent that the induction of a class of interferon (IFN)--producing CD4+ T helper cells (TH1 cells) that activate macrophages to kill the parasites they harbor is desicive for the establishment of immunity. The redirection of the host’s immune response towards a protective TH1 phenotype will also be the key to an effective vaccine. Dendritic cells (DC) loaded with leishmanial antigens ex vivo were lately described as vaccines against L. major infections. One single recombinant Leishmania antigen, LeIF (Leishmania homologue of eukaryotic ribosomal initiation factor 4a), which was identified as a protein that stimulates DC to secrete interleukin (IL)-12 and discussed as a pattern-associated molecular pattern (PAMP), was found to mediate a protective TH1-dependent effect when used for pulsing of DC. The application of recombinant proteins is tied to many disadvantages, which is why other methods of antigen administration have been developed. RNA electroporation of DC has recently emerged from tumor research as a safe and versatile method of antigen delivery, by which a large number of RNA molecules encoding a specific antigen gains access to the cytosol of DC by an electrical impulse. The present study describes, for the first time, transfection of DC with RNA encoding a molecularly defined parasite antigen. Initially, a standardized protocol for RNA transfection was established, using the enhanced green fluorescent protein (EGFP) as reporter antigen. EGFP-RNA was well translatable in an in vitro translation system, and both a DC cell line (fetal skin-derived DC; FSDC) and murine primary bone marrow-derived DC (BMDC) could be transfected efficiently, with a yield of up to 90% and 75%, respectively. In both cell types, maximal transfection efficiency was attained with 20 µg RNA and could not be further increased with larger amounts of RNA. The level of antigen expression, measured as the mean fluorescence intensity (MFI) by flow cytometry, was directly proportional to the amount of RNA used for transfection. In FSDC, transfection efficiency and MFI were generally higher than in BMDC when the same amounts of RNA were used. Furthermore, the kinetics was shown to be sensitive to treatment with lipopolysaccharide (LPS): the expression peak was higher and was reached sooner, followed by a more rapid decline. In transfection experiments with LeIF, two variants of LeIF-RNA were used: LeIF(fl)-RNA, encoding the complete LeIF sequence, and LeIF(226)-RNA, encoding only the aminoterminal half of the LeIF sequence (226 amino acids), the immunogenic part of LeIF. Only LeIF(fl) was detectable by Western Blot in whole cell lysates of BMDC after LeIF(fl)-RNA transfection, whereas LeIF(226) could never be detected in LeIF(226)-transfected BMDC. However, as both constructs were well translatable in a cell-free system, the failure to detect LeIF(226) in BMDC lysates did not represent a failure in RNA translation, but rather a rapid antigen degradation. It was therefore expected that LeIF(226)-transfected BMDC should nevertheless be able to present LeIF(226)-derived antigenic peptides to T cells from BALB/c mice primed with recombinant LeIF (rLeIF). This hypothesis was confirmed by measuring IFN- production in BMDC-T cell co-incubation assays, showing that rLeIF-pulsed, LeIF(226)- and LeIF(fl)-transfected day 7 BMDC did indeed activate T cells from LeIF-immunized mice in an antigen-specific manner. In contrast, IL-4 was not produced, which was consistent with the fact that T cells found in lymph nodes from LeIF-primed mice are primarily of the TH1 type. In the supernatants of LeIF-transfected BMDC cultures, in contrast to rLeIF-pulsed BMDC, the proinflammatory cytokines IL-1β, IL-6, IL-10 and IL-12 were not detected. This effect was not due to the electroporation procedure, as cytokine production by BMDC electroporated with rLeIF was only partially impaired. Also, the expression levels of CD86 were lower upon LeIF transfection than after pulsing with rLeIF. Thus, LeIF transfection did not induce maturation of DC. In conclusion, LeIF-transfected BMDC may have acted as semi-mature antigen-specific tolerance inducers, with regulatory T cells as responders. The effect of LeIF transfection on the immunostimulatory capacity of BMDC was not significantly increased when day 8 or 9 BMDC were used. However, day 8, and even more day 9 BMDC pulsed with rLeIF mounted a vigorous T cell response. Day 9 BMDC were able to activate naïve T cells. In conclusion, before a strong T cell response against LeIF can be induced, DC need to – besides presenting antigen and expressing co-stimulatory molecules – exhibit a susceptibility to the innate signaling molecule LeIF which is linked to their maturation age. This third signal is provided by extracellular rLeIF, but it is not conveyed – or is suppressed – by intracellular LeIF after LeIF-RNA transfection. Furthermore, electroporation of rLeIF abrogated IL-12 production by BMDC completely, the production of IL-1 was reduced with higher antigen doses, and the production of IL-10 was partially increased. The IL-6 production was unaffected. This altered cytokine profile suggests that LeIF as a PAMP might have a bipartite nature: besides exhibiting the capacity to stimulate IL-12 production upon extracellular presence, thereby enhancing host resistance against L. major, LeIF could also contribute to parasitic host evasion mechanisms from intracellular compartments of DC, possibly by interfering with mitogen-activated protein (MAP) kinase signaling pathways. Thus, the adjuvant properties of LeIF depend both on its mode of delivery (transfection with RNA vs. pulsing with the recombinant protein) and the targeted compartment (extra- vs. intracellular). From this work, it can be summarized that BMDC are well transfectable with a parasite antigen. The antigen is processed and presented, but it is not recognized as a PAMP by DC. Hence, transfection with antigen-encoding mRNA by itself does not convey all necessary signals for the elicitation of a potent immune response. KW - Elektroporation KW - Leishmania KW - Leishmania major KW - Immunbiologie KW - Immunologie KW - Dendritische Zelle KW - Transfektion KW - Impfung KW - Antigenpräsentation KW - EGFP KW - pathogen-associated molecular pattern KW - TH1/TH2 KW - Transfektion KW - EGFP KW - pathogen-associated molecular pattern KW - TH1/TH2 KW - transfection Y1 - 2007 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-26208 ER - TY - JOUR A1 - Heidegger, Simon A1 - Beer, Ambros J. A1 - Geissinger, Eva A1 - Rosenwald, Andreas A1 - Peschel, Christian A1 - Ringshausen, Ingo A1 - Keller, Ulrich T1 - Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma JF - Oncotargets and Therapy N2 - Anaplastic large cell lymphoma (ALCL) is a common subtype of the heterogeneous group of peripheral T-cell lymphomas, which is characterized by large pleomorphic cells with strong expression of CD30. Translocations involving ALK, the anaplastic lymphoma kinase gene, are associated with a favorable clinical outcome. Such ALK-positive ALCLs are usually responsive to a multidrug chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). However, there is no general consensus on the optimal therapy for relapsed or refractory ALCL. We report the case of a 24-year-old male suffering from ALK-positive ALCL with an uncommon manifestation of only extranodal disease in the gastric cardia region that showed primary refractoriness to standard CHOP chemotherapy. A combination therapy consisting of the anti-CD30 drug conjugate, brentuximab vedotin, and classical lymphoma salvage regimen DHAP (cisplatin, high-dose cytarabine and dexamethasone) was administered. Following two treatment cycles in 21-day intervals, the lymphoma showed considerable regression based on imaging diagnostics and no evidence of vital lymphoma in a subsequent biopsy. We did not observe any increase in toxicity; in particular, polyneuropathy and febrile neutropenia were not observed. In summary, we report that the antibody-drug conjugate brentuximab vedotin and a classical regimen used for aggressive lymphoma, DHAP, could be combined as salvage therapy in a case of refractory ALK-positive ALCL. Phase I/II studies will be required for safety and efficacy analysis. KW - anti-CD30 drug conjugate KW - DHAP KW - refractory/relapsed lymphoma KW - SGN-35 KW - anaplastic large cell lymphoma (ALCL) KW - combined therapy KW - high-dose chemotherapy KW - peripheral T-cell KW - marrow transplantation Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-117901 VL - 7 ER - TY - JOUR A1 - Graf, Nicolas A1 - Li, Zhoulei A1 - Herrmann, Ken A1 - Weh, Daniel A1 - Aichler, Michaela A1 - Slawska, Jolanta A1 - Walch, Axel A1 - Peschel, Christian A1 - Schwaiger, Markus A1 - Buck, Andreas K. A1 - Dechow, Tobias A1 - Keller, Ulrich T1 - Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma JF - Oncotargets and Therapy N2 - Background: Dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibition offers an attractive therapeutic strategy in anaplastic large cell lymphoma depending on oncogenic nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) signaling. We tested the efficacy of a novel dual PI3K/mTOR inhibitor, NVP-BGT226 (BGT226), in two anaplastic large cell lymphoma cell lines in vitro and in vivo and performed an early response evaluation with positron emission tomography (PET) imaging using the standard tracer, 2-deoxy-2-[F-18] fluoro-D-glucose (FDG) and the thymidine analog, 3'-deoxy-3'-[F-18] fluorothymidine (FLT). Methods: The biological effects of BGT226 were determined in vitro in the NPM-ALK positive cell lines SU-DHL-1 and Karpas299 by 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay, propidium iodide staining, and biochemical analysis of PI3K and mTOR downstream signaling. FDG-PET and FLT-PET were performed in immunodeficient mice bearing either SU-DHL-1 or Karpas299 xenografts at baseline and 7 days after initiation of treatment with BGT226. Lymphomas were removed for immunohistochemical analysis of proliferation and apoptosis to correlate PET findings with in vivo treatment effects. Results: SU-DHL-1 cells showed sensitivity to BGT226 in vitro, with cell cycle arrest in G0/G1 phase and an IC50 in the low nanomolar range, in contrast with Karpas299 cells, which were mainly resistant to BGT226. In vivo, both FDG-PET and FLT-PET discriminated sensitive from resistant lymphoma, as indicated by a significant reduction of tumor-to-background ratios on day 7 in treated SU-DHL-1 lymphoma-bearing animals compared with the control group, but not in animals with Karpas299 xenografts. Imaging results correlated with a marked decrease in the proliferation marker Ki67, and a slight increase in the apoptotic marker, cleaved caspase 3, as revealed by immunostaining of explanted lymphoma tissue. Conclusion: Dual PI3K/mTOR inhibition using BGT226 is effective in ALK-positive anaplastic large cell lymphoma and can be monitored with both FDG-PET and FLT-PET early on in the course of therapy. KW - mammalian target of rapamycin KW - phosphatidylinositol-3-kinase KW - lymphoma KW - early response KW - NVP-BGT226 KW - non-hodgkins-lymphoma KW - signaling pathway KW - FDG-PET KW - in-vivo KW - target KW - tumor KW - imaging proliferation KW - inhibition KW - positron emission tomography Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-117915 VL - 7 ER - TY - JOUR A1 - Philipp-Abbrederis, Kathrin A1 - Herrmann, Ken A1 - Knop, Stefan A1 - Schottelius, Margret A1 - Eiber, Matthias A1 - Lückerath, Katharina A1 - Pietschmann, Elke A1 - Habringer, Stefan A1 - Gerngroß, Carlos A1 - Franke, Katharina A1 - Rudelius, Martina A1 - Schirbel, Andreas A1 - Lapa, Constantin A1 - Schwamborn, Kristina A1 - Steidle, Sabine A1 - Hartmann, Elena A1 - Rosenwald, Andreas A1 - Kropf, Saskia A1 - Beer, Ambros J A1 - Peschel, Christian A1 - Einsele, Hermann A1 - Buck, Andreas K A1 - Schwaiger, Markus A1 - Götze, Katharina A1 - Wester, Hans-Jürgen A1 - Keller, Ulrich T1 - In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma JF - EMBO Molecular Medicine N2 - CXCR4 is a G-protein-coupled receptor that mediates recruitment of blood cells toward its ligand SDF-1. In cancer, high CXCR4 expression is frequently associated with tumor dissemination andpoor prognosis. We evaluated the novel CXCR4 probe [\(^{68}\)Ga]Pentixafor for invivo mapping of CXCR4 expression density in mice xenografted with human CXCR4-positive MM cell lines and patients with advanced MM by means of positron emission tomography (PET). [\(^{68}\)Ga]Pentixafor PET provided images with excellent specificity and contrast. In 10 of 14 patients with advanced MM [\(^{68}\)Ga]Pentixafor PET/CT scans revealed MM manifestations, whereas only nine of 14 standard [\(^{18}\)F]fluorodeoxyglucose PET/CT scans were rated visually positive. Assessment of blood counts and standard CD34\(^{+}\) flow cytometry did not reveal significant blood count changes associated with tracer application. Based on these highly encouraging data on clinical PET imaging of CXCR4 expression in a cohort of MM patients, we conclude that [\(^{68}\)Ga]Pentixafor PET opens a broad field for clinical investigations on CXCR4 expression and for CXCR4-directed therapeutic approaches in MM and other diseases. KW - FDG PET/CT KW - cells KW - CXCR4/SDF-1 KW - CXCR4 KW - multiple myeloma KW - positron emission tomography KW - chemokine receptor KW - in vivo imaging KW - malignancies KW - involvement KW - microenvironment KW - survival KW - cancer KW - autologous transplantation KW - bone disease Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-148738 VL - 7 IS - 4 ER - TY - JOUR A1 - Hofmann, Ulf Krister A1 - Keller, Ramona Luise A1 - Walter, Christian A1 - Mittag, Falk T1 - Predictability of the effects of facet joint infiltration in the degenerate lumbar spine when assessing MRI scans JF - Journal of Orthopaedic Surgery and Research N2 - Background Imaging results are frequently considered as hallmarks of disease by spine surgeons to plan their future treatment strategy. Numerous classification systems have been proposed to quantify or grade lumbar magnetic resonance imaging (MRI) scans and thus objectify imaging findings. The clinical impact of the measured parameters remains, however, unclear. To evaluate the pathological significance of imaging findings in patients with multisegmental degenerative findings, clinicians can perform image-guided local infiltrations to target defined areas such as the facet joints. The aim of the present retrospective study was to evaluate the correlation of MRI facet joint degeneration and spinal stenosis measurements with improvement obtained by image-guided intraarticular facet joint infiltration. Methods Fifty MRI scans of patients with chronic lumbar back pain were graded radiologically using a wide range of classification and measurement systems. The reported effect of facet joint injections at the site was recorded, and a comparative analysis performed. Results When we allocated patients according to their reported pain relief, 27 showed no improvement (0–30%), 16 reported good improvement (31–75%) and 7 reported excellent improvement (> 75%). MRI features assessed in this study did, however, not show any relevant correlation with reported pain after facet joint infiltration: Values for Kendall’s tau ranged from \(\tau\) = − 0.190 for neuroforaminal stenosis grading as suggested by Lee, to \(\tau\) = 0.133 for posterior disc height as proposed by Hasegawa. Conclusion Despite the trend in evidence-based medicine to provide medical algorithms, our findings underline the continuing need for individualised spine care that, along with imaging techniques or targeted infiltrations, includes diagnostic dimensions such as good patient history and clinical examination to formulate a diagnosis. Trial registration ClinicalTrials.gov, NCT03308149, retrospectively registered October 2017 KW - medicine KW - lumbar spinal stenosis KW - lumbar degenerative disease KW - MRI KW - facet joint degeneration KW - facet joint injection Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-173027 VL - 12 ER -